Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.

Chan KC, Ting CM, Chan PS, Lo MC, Lo KW, Curry JE, Smyth T, Lee AW, Ng WT, Tsao GS, Wong RN, Lung ML, Mak NK.

Mol Cancer. 2013 Oct 24;12(1):128. doi: 10.1186/1476-4598-12-128.

2.

CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma.

Lun SW, Cheung ST, Cheung PF, To KF, Woo JK, Choy KW, Chow C, Cheung CC, Chung GT, Cheng AS, Ko CW, Tsao SW, Busson P, Ng MH, Lo KW.

PLoS One. 2012;7(12):e52426. doi: 10.1371/journal.pone.0052426. Epub 2012 Dec 21.

3.

Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.

Chan KC, Chan LS, Ip JC, Lo C, Yip TT, Ngan RK, Wong RN, Lo KW, Ng WT, Lee AW, Tsao GS, Kahn M, Lung ML, Mak NK.

Sci Rep. 2015 Apr 21;5:9979. doi: 10.1038/srep09979.

4.

MicroRNA-183 suppresses cancer stem-like cell properties in EBV-associated nasopharyngeal carcinoma.

Cheung CC, Lun SW, Chung GT, Chow C, Lo C, Choy KW, Lo KW.

BMC Cancer. 2016 Jul 19;16:495. doi: 10.1186/s12885-016-2525-5.

5.

The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.

Smyth T, Van Looy T, Curry JE, Rodriguez-Lopez AM, Wozniak A, Zhu M, Donsky R, Morgan JG, Mayeda M, Fletcher JA, Schöffski P, Lyons J, Thompson NT, Wallis NG.

Mol Cancer Ther. 2012 Aug;11(8):1799-808. doi: 10.1158/1535-7163.MCT-11-1046. Epub 2012 Jun 19.

6.

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.

Graham B, Curry J, Smyth T, Fazal L, Feltell R, Harada I, Coyle J, Williams B, Reule M, Angove H, Cross DM, Lyons J, Wallis NG, Thompson NT.

Cancer Sci. 2012 Mar;103(3):522-7. doi: 10.1111/j.1349-7006.2011.02191.x. Epub 2012 Feb 9.

7.

Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.

Spiegelberg D, Mortensen AC, Selvaraju RK, Eriksson O, Stenerlöw B, Nestor M.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):974-82. doi: 10.1007/s00259-015-3260-x. Epub 2015 Dec 1.

8.

The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.

Spiegelberg D, Dascalu A, Mortensen AC, Abramenkovs A, Kuku G, Nestor M, Stenerlöw B.

Oncotarget. 2015 Nov 3;6(34):35652-66. doi: 10.18632/oncotarget.5363.

9.

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA.

Pediatr Blood Cancer. 2012 Jul 15;59(1):185-8. doi: 10.1002/pbc.23154. Epub 2011 Apr 29.

10.

Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.

Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GS, Chiang AK.

Int J Cancer. 2012 Oct 15;131(8):1930-40. doi: 10.1002/ijc.27439. Epub 2012 Mar 8.

11.

FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition.

Ye M, Huang W, Wu WW, Liu Y, Ye SN, Xu JH.

Oncotarget. 2017 Feb 28;8(9):15364-15376. doi: 10.18632/oncotarget.14970.

12.

Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells.

Mei YP, Zhou JM, Wang Y, Huang H, Deng R, Feng GK, Zeng YX, Zhu XF.

Cell Cycle. 2007 Jun 1;6(11):1379-85. Epub 2007 Jun 11.

PMID:
17507800
13.

Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.

Ma L, Zhang G, Miao XB, Deng XB, Wu Y, Liu Y, Jin ZR, Li XQ, Liu QZ, Sun DX, Testa JR, Yao KT, Xiao GH.

FEBS J. 2013 May;280(9):2027-41. doi: 10.1111/febs.12226. Epub 2013 Apr 8.

14.

Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.

Chiu SH, Wu CC, Fang CY, Yu SL, Hsu HY, Chow YH, Chen JY.

Oncotarget. 2014 Sep 30;5(18):8583-601.

15.
16.

Pectolinarigenin Suppresses the Tumor Growth in Nasopharyngeal Carcinoma.

Wang C, Cheng Y, Liu H, Xu Y, Peng H, Lang J, Liao J, Liu H, Liu H, Fan J.

Cell Physiol Biochem. 2016;39(5):1795-1803. Epub 2016 Oct 17.

17.

Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts.

Tsang CM, Cheung YC, Lui VW, Yip YL, Zhang G, Lin VW, Cheung KC, Feng Y, Tsao SW.

BMC Cancer. 2013 Dec 31;13:619. doi: 10.1186/1471-2407-13-619.

18.

mTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo.

Yang C, Peng J, Jiang W, Zhang Y, Chen X, Wu X, Zhu Y, Zhang H, Chen J, Wang J, Cho WC, Jin K.

Cancer Lett. 2013 Dec 1;341(2):186-94. doi: 10.1016/j.canlet.2013.08.004. Epub 2013 Aug 7.

PMID:
23933173
19.

Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma.

Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH, Liang Y, Xiong D, Guan S, Guo BH, Mai HQ, Chen QY, Zhang X, Li MZ, Shao JY, Qian CN, Xia YF, Song LB, Zeng YX, Zeng MS.

PLoS Pathog. 2010 Jun 3;6(6):e1000940. doi: 10.1371/journal.ppat.1000940.

20.

Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.

Abdulkarim B, Sabri S, Zelenika D, Deutsch E, Frascogna V, Klijanienko J, Vainchenker W, Joab I, Bourhis J.

Oncogene. 2003 Apr 17;22(15):2260-71.

PMID:
12700662

Supplemental Content

Support Center